Astrazeneca (AZN) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Astrazeneca (AZN) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
76.51% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
131.31% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
109.43% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
178.93% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
14.82% |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
-7.00% |
| Date | Value |
|---|
| Mar 31, 2026 |
178.93% |
| Dec 31, 2025 |
17.40% |
| Sep 30, 2025 |
-58.15% |
| Jun 30, 2025 |
396.26% |
| Mar 31, 2025 |
114.86% |
| Dec 31, 2024 |
58.85% |
| Sep 30, 2024 |
182.50% |
| Jun 30, 2024 |
166,152.94% |
| Mar 31, 2024 |
1,123.40% |
| Dec 31, 2023 |
6.17% |
| Sep 30, 2023 |
45.02% |
| Jun 30, 2023 |
146,248.62% |
| Dec 31, 2022 |
39.64% |
| Jun 30, 2022 |
-154,846.22% |
| Dec 31, 2021 |
-27.63% |
| Sep 30, 2021 |
-30.39% |
| Jun 30, 2021 |
-99.97% |
| Dec 31, 2020 |
13.27% |
| Jun 30, 2020 |
-99.90% |
| Dec 31, 2019 |
-23.07% |
